COMP Peptide Antibody Detection for Early Osteoarthritis Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing early stages of osteoarthritis and atherosclerosis are inadequate, as they rely on expensive equipment and cannot detect structural changes until late stages, and there is a need for more convenient and effective markers for monitoring these conditions.
Innovation Solution
Development of an antibody that specifically binds to the N-terminal-SGPTH peptide (SEQ ID NO: 1) for diagnosing systemic low-grade chronic inflammatory diseases, including osteoarthritis and atherosclerosis, by measuring its presence in synovial fluid or blood samples using ELISA or immunohistochemistry.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If X-ray or MRI examination is used to diagnose osteoarthritis, then structural damages can be visualized, but the method cannot detect early stage OA before irreversible structural damages occur, and requires expensive equipment and specialized radiologists
Solution Approach 1:
The patent identifies and measures COMP peptide fragments before irreversible structural damages occur. By detecting this biomarker in synovial fluid or blood, the invention enables early diagnosis of osteoarthritis at stages preceding visible structural changes on X-ray or MRI, thus performing the detection action in advance before the disease manifests structurally
Solution Approach 2:
The COMP peptide fragment serves as an intermediary biomarker that mediates between the underlying pathological process of osteoarthritis and the diagnostic method. Instead of directly visualizing structural damage, the invention measures this intermediate molecular marker that appears earlier in the disease progression, bridging the gap between early pathology and detectable structural changes
2Reliability
If ultrasound is used to diagnose carotid stenosis, then plaques can be detected, but the method has moderate sensitivity and specificity and cannot reliably monitor progression to dangerous phases
Solution Approach 1:
The patent measures changes in COMP peptide fragment concentration in blood or serum samples as a quantitative parameter to monitor atherosclerosis progression. This biochemical parameter provides more reliable and precise measurement compared to ultrasound imaging, enabling accurate detection and monitoring of progression from early plaques to dangerous phases with higher sensitivity and specificity
3Productivity
If early markers for osteoarthritis are identified, then drug development can be facilitated and treatment can be initiated before irreversible damage, but no such markers have been available until now
Solution Approach 1:
The patent extracts and identifies the COMP peptide fragment as a specific early biomarker for osteoarthritis. By isolating this particular molecular marker from the complex synovial fluid or blood sample, the invention provides a clear, actionable signal that enables early detection and facilitates drug development by providing target information for interventions before irreversible structural damage occurs
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early detection and monitoring of osteoarthritis and atherosclerosis, facilitating drug development and reducing the economic impact of osteoarthritis in horses, and providing a cost-effective alternative to existing diagnostic methods.
Implementation Method 1
an antibody that specifically binds to a peptide comprising the amino acid sequence N-terminal-SGPTH
Implementation Method 2
measuring its presence in synovial fluid or blood samples using ELISA or immunohistochemistry
Implementation Method 3
measuring its presence in synovial fluid or blood samples using ELISA or immunohistochemistry
Data Source
AI summary
There is provided a peptide comprising the amino acid se-quence N-terminal-SGPTH and an antibody against this peptide. The peptide can be used for diagnosis in humans and animals, in particular horses. In particular the antibody can be used for diagnosis of a systemic low-grade chronic inflammatory disease such as osteoarthritis or atherosclerosis, or a neurodegenerative disease or neuroinflammatory disease.